Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Stock Performance

Shares of EVGN opened at $1.73 on Monday. The company has a 50 day moving average price of $2.49 and a 200-day moving average price of $4.61. Evogene has a fifty-two week low of $1.70 and a fifty-two week high of $10.40. The stock has a market capitalization of $9.29 million, a PE ratio of -0.44 and a beta of 1.43.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The firm had revenue of $0.91 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.